TY - JOUR
T1 - Impact of the COVID-19 Pandemic on Cancer Clinical Trials
AU - Boughey, Judy C.
AU - Snyder, Rebecca A.
AU - Kantor, Olga
AU - Zheng, Linda
AU - Chawla, Akhil
AU - Nguyen, Toan T.
AU - Hillman, Shauna L.
AU - Hahn, Olwen M.
AU - Mandrekar, Sumithra J.
AU - Roland, Christina L.
N1 - Funding Information:
Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under award number U10CA180882 (to the Alliance for Clinical Trials in Oncology Statistics and Data Management Center Health). https://acknowledgments.alliancefound.org .
Publisher Copyright:
© 2021, Society of Surgical Oncology.
PY - 2021/11
Y1 - 2021/11
N2 - The COVID-19 pandemic has had widespread impact on healthcare, resulting in modifications to how we perform cancer research, including clinical trials for cancer. The impact of some healthcare workers and study coordinators working remotely and patients minimizing visits to medical facilities impacted clinical trial participation. Clinical trial accrual dropped at the onset of the pandemic, with improvement over time. Adjustments were made to some trial protocols, allowing telephone or video-enabled consent. Certain study activities were permitted to be performed by local healthcare providers or at local laboratories to maximize patients’ ability to continue on study during these challenging times. We discuss the impact of COVID-19 on cancer clinical trials and changes at the local, cooperative group, and national level.
AB - The COVID-19 pandemic has had widespread impact on healthcare, resulting in modifications to how we perform cancer research, including clinical trials for cancer. The impact of some healthcare workers and study coordinators working remotely and patients minimizing visits to medical facilities impacted clinical trial participation. Clinical trial accrual dropped at the onset of the pandemic, with improvement over time. Adjustments were made to some trial protocols, allowing telephone or video-enabled consent. Certain study activities were permitted to be performed by local healthcare providers or at local laboratories to maximize patients’ ability to continue on study during these challenging times. We discuss the impact of COVID-19 on cancer clinical trials and changes at the local, cooperative group, and national level.
UR - http://www.scopus.com/inward/record.url?scp=85110873428&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85110873428&partnerID=8YFLogxK
U2 - 10.1245/s10434-021-10406-2
DO - 10.1245/s10434-021-10406-2
M3 - Article
C2 - 34236550
AN - SCOPUS:85110873428
SN - 1068-9265
VL - 28
SP - 7311
EP - 7316
JO - Annals of surgical oncology
JF - Annals of surgical oncology
IS - 12
ER -
